EOM Pharmaceutical (IMUC) Stock Price, News & Analysis

Company Overview

EOM Pharmaceutical (OTCMKTS:IMUC) is a development-stage biopharmaceutical company focused on the research and development of novel therapies in immuno-oncology and metabolic disease. The firm’s core expertise lies in designing cell-based immunotherapies aimed at enhancing the body’s own immune response against aggressive solid tumors. Alongside its lead oncology programs, EOM Pharmaceutical has initiated early-stage discovery efforts in metabolic disorders, seeking to leverage its translational research platform across multiple therapeutic areas.

The company’s pipeline features personalized dendritic cell vaccines engineered to target tumor-specific antigens in glioblastoma multiforme and other central nervous system malignancies. Preclinical assets include next-generation immune checkpoint modulators and combination strategies intended to overcome resistance mechanisms in solid tumors. In the metabolic disease arena, EOM is advancing small-molecule candidates designed to regulate key pathways in insulin sensitivity and lipid metabolism.

Headquartered in Homestead, Florida, EOM Pharmaceutical operates research and manufacturing facilities in North America and maintains strategic collaborations with leading academic centers in the United States and Europe. These partnerships provide access to specialized laboratory resources, advanced clinical trial networks and state-of-the-art biomanufacturing expertise. The company’s global footprint also encompasses regulatory affairs teams in both the U.S. and the European Union to support future registration filings.

EOM Pharmaceutical’s leadership team brings together seasoned executives from top pharmaceutical and biotech firms. Chief Executive Officer Dr. Alan Brown has more than 25 years of experience in oncology drug development, while Chief Scientific Officer Dr. Maria Martinez is recognized for her work in translational immunology and vaccine platforms. The board of directors includes industry veterans and clinical researchers who guide the company’s strategic direction and oversee its commitment to advancing novel therapies from bench to bedside.

Key Stats

• Today's Range: $0.08 to $0.08
• 50-Day Range: $0.06 to $0.11
• 52-Week Range: $0.01 to $0.21
• Volume: 106 shs
• Average Volume: 716 shs
• Market Capitalization: $9.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMUC Stock Analysis - Frequently Asked Questions

How have IMUC shares performed this year?

EOM Pharmaceutical's stock was trading at $0.1688 at the start of the year. Since then, IMUC stock has decreased by 54.3% and is now trading at $0.0771.

How were EOM Pharmaceutical's earnings last quarter?

EOM Pharmaceutical Holdings, Inc. (OTCMKTS:IMUC) announced its quarterly earnings results on Monday, August, 13th. The company reported ($0.01) EPS for the quarter.

How do I buy shares of EOM Pharmaceutical?

Shares of IMUC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of EOM Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that EOM Pharmaceutical investors own include Argos Therapeutics (ARGSQ), Nightfood (NGTF), Meta Platforms (META), LadRx (CYTR), Inovio Pharmaceuticals (INO), MannKind (MNKD) and Agenus (AGEN).

Company Calendar

• Last Earnings: 8/13/2018
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:IMUC
• CIK: 822411
• Web: www.imuc.com
• Phone: (201) 351-0605
• Fax: 818-224-5287
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,500,000
• Free Float: 122,354,000
• Market Cap: $9.75 million
• Optionable: Not Optionable
• Beta: -0.01